BASSO, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.420
AS - Asia 1.660
EU - Europa 1.246
AF - Africa 474
SA - Sud America 469
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 25
AN - Antartide 1
Totale 9.339
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.153
SG - Singapore 486
CN - Cina 336
BR - Brasile 295
IT - Italia 239
HK - Hong Kong 228
DE - Germania 133
VN - Vietnam 125
FI - Finlandia 120
SE - Svezia 62
PL - Polonia 59
NL - Olanda 56
FR - Francia 51
GB - Regno Unito 51
RU - Federazione Russa 45
BE - Belgio 30
AT - Austria 27
IN - India 27
CA - Canada 26
KR - Corea 25
IQ - Iraq 24
AR - Argentina 23
UA - Ucraina 22
CO - Colombia 21
MA - Marocco 21
PY - Paraguay 21
TR - Turchia 21
VE - Venezuela 21
AZ - Azerbaigian 20
IE - Irlanda 20
PR - Porto Rico 20
AM - Armenia 19
JO - Giordania 19
KH - Cambogia 19
BB - Barbados 18
DO - Repubblica Dominicana 18
EG - Egitto 18
ES - Italia 18
PE - Perù 18
RO - Romania 18
ZA - Sudafrica 18
AO - Angola 17
EC - Ecuador 17
IL - Israele 17
BO - Bolivia 16
GA - Gabon 16
ID - Indonesia 16
KG - Kirghizistan 16
MU - Mauritius 16
RS - Serbia 16
SO - Somalia 16
DZ - Algeria 15
EE - Estonia 15
HR - Croazia 15
KE - Kenya 15
MD - Moldavia 15
MK - Macedonia 15
PA - Panama 15
PS - Palestinian Territory 15
PT - Portogallo 15
SN - Senegal 15
BD - Bangladesh 14
CH - Svizzera 14
CI - Costa d'Avorio 14
DK - Danimarca 14
GT - Guatemala 14
LU - Lussemburgo 14
LV - Lettonia 14
ME - Montenegro 14
MN - Mongolia 14
MX - Messico 14
MZ - Mozambico 14
NE - Niger 14
NP - Nepal 14
RE - Reunion 14
TN - Tunisia 14
UY - Uruguay 14
AU - Australia 13
BY - Bielorussia 13
CR - Costa Rica 13
DJ - Gibuti 13
IS - Islanda 13
JM - Giamaica 13
LY - Libia 13
MW - Malawi 13
MY - Malesia 13
PH - Filippine 13
SA - Arabia Saudita 13
SI - Slovenia 13
UZ - Uzbekistan 13
XK - ???statistics.table.value.countryCode.XK??? 13
BS - Bahamas 12
CD - Congo 12
CL - Cile 12
CM - Camerun 12
CU - Cuba 12
GR - Grecia 12
HU - Ungheria 12
KZ - Kazakistan 12
MG - Madagascar 12
Totale 8.818
Salva come PNG Salva come JPEG
Città #
Fairfield 900
Woodbridge 459
Ashburn 457
Houston 406
Chandler 391
Seattle 328
Cambridge 301
Singapore 292
Wilmington 273
Ann Arbor 230
Hong Kong 211
Beijing 114
Boardman 109
Santa Clara 100
San Diego 89
Princeton 84
Jacksonville 73
Des Moines 56
Padova 56
Los Angeles 55
Dong Ket 50
Roxbury 49
Bytom 44
Munich 43
Helsinki 41
Medford 40
Chicago 34
Nanjing 31
Ho Chi Minh City 25
Falls Church 24
São Paulo 23
Turku 23
Hefei 21
Milan 21
New York 20
Vienna 19
Baku 18
Buffalo 18
London 18
Nanchang 18
Amman 17
Bridgetown 17
Dublin 17
Guangzhou 16
Phnom Penh 16
Bishkek 15
Libreville 15
Luanda 15
Nuremberg 15
Tallinn 15
Yerevan 15
Dakar 14
Hanoi 14
Seoul 14
Ulan Bator 14
Lappeenranta 13
Panama City 13
Reykjavik 13
Riga 13
Rome 13
San José 13
Abidjan 12
Bamako 12
Boston 12
Nairobi 12
Niamey 12
Podgorica 12
Castries 11
Djibouti 11
Havana 11
Kinshasa 11
Managua 11
Nassau 11
Santa Cruz 11
Tashkent 11
Tripoli 11
Amsterdam 10
Antananarivo 10
Belgrade 10
Conakry 10
Falkenstein 10
Kampala 10
Kingston 10
Lima 10
Maputo 10
Montevideo 10
San Juan 10
Skopje 10
Stockholm 10
Tunis 10
Vientiane 10
Willemstad 10
Andorra la Vella 9
Ankara 9
Brussels 9
Frankfurt am Main 9
Lilongwe 9
Port Moresby 9
Salt Lake City 9
Toronto 9
Totale 6.274
Salva come PNG Salva come JPEG
Nome #
Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection 247
Viral infections of the central nervous system in elderly patients: A retrospective study 233
Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy. 216
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin 213
Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: Complexity and vaccine implications 209
Epstein-Barr and cytomegalovirus DNA salivary shedding correlate with long-term plasma HIV RNA detection in HIV-infected men who have sex with men 208
Prevalence of Klebsiella pneumoniae strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 To December 2014 207
Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1–HCV co-infected patients on effective combined anti-HIV treatment 202
Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma 191
Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy 190
Virological testing of cerebrospinal fluid in children aged less than 14 years with a suspected central nervous system infection: A retrospective study on 304 consecutive children from January 2012 to May 2015 175
A case of persistent bacteraemia by Ralstonia mannitolilytica and Ralstonia pickettii in an intensive care unit 173
Peripheral blood serum markers for apoptosis and liver fibrosis: are they trustworthy indicators of liver realness? 152
Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver 151
Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. 149
Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: A 24-month longitudinal study 149
Baseline Cellular HIV DNA Load Predicts HIV DNA Decline and Residual HIV Plasma Levels during Effective Antiretroviral Therapy. 146
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 145
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 140
Long-term therapy with nevirapine and tropism 140
Structural-equation-modelling of the tropism impact on achieving viral suppression within six months in naïve HIV patients. 137
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. 135
Intra-hospital acquisition of colonization and infection by Klebsiella pneumoniae strains producing carbapenemases and carriage evolution: A longitudinal analysis in an Italian teaching hospital from January 2017 to August 2019 135
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 134
Prevalence, molecular epidemiology and intra-hospital acquisition of Klebsiella pneumoniae strains producing carbapenemases in an Italian teaching hospital from January 2015 to September 2016. 134
Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects recently diagnosed as HIV-infected over the period 2004–2012 in the Veneto Region, Italy 133
Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach 131
Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. 130
HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection 130
Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. 127
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 126
Detection of hepatitis C virus in an exhumed body identified the origin of a nosocomial transmission that caused multiple fatal diseases 126
Viral molecular testing of cerebrospinal fluid in adults with suspected central nervous system infection in an italian university hospital laboratory: A retrospective study on 1462 consecutive patients 126
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors 125
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 122
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. 121
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 121
Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. 121
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C. 120
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects 120
Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention 118
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. 116
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. 115
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals 115
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 114
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant. 113
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden. 112
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. 110
Sustained Virological Response and Baseline Predictors in HIV-HCV Coinfected Patients Retreated with Pegylated Interferon and Ribavirin after Failing a Previous Interferon-Based Therapy: Systematic Review and Meta-Analysis 110
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 109
BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects 107
[Nailfold videocapillaroscopy in systemic sclerosis: diagnostic and follow-up parameters and correlation with both specific serum autoantibodies and subsets of skin involvement]. 106
HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study 106
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals 106
Hbcab positivity is a risk factor for an increased detectability of hiv rna after switching to a two-drug regimen lamivudine-based (2dr-3tc-based) treatment: Analysis of a multicenter italian cohort 106
Sustained virological response after treatment with direct-acting antivirals can help immune reconstitution in HIV-HCV coinfected patients even in case of persistent HIV low-level viremia 106
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. 105
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 104
Patterns of Transmitted Drug Resistance Mutations and HIV-1 Subtype Dynamics in ART-Naïve Individuals in Veneto, Italy, from 2017 to 2024 97
Time Course of Neutralizing Antibody in Health Care Workers with Mild or Asymptomatic COVID-19 Infection 95
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 93
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 93
Humoral Response after Two Doses of BNT162b2 mRNA Vaccine Has a Role in Predicting Response after Three Doses That Is Related to Plasma HIV Viremia and Nadir CD4+ Cell Count in HIV-Positive Patients 92
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 91
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 85
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumor necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 84
null 81
Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study 77
Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study 73
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 71
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 65
HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch 62
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. 57
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients. 56
Totale 9.440
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.283
article - articoli 31.283
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.566
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021631 0 0 0 94 29 33 39 106 81 68 99 82
2021/20221.054 22 142 103 42 40 41 60 82 131 21 183 187
2022/2023759 141 85 16 96 127 101 3 59 80 5 34 12
2023/2024349 17 40 43 33 21 25 31 26 8 25 34 46
2024/20251.595 5 63 39 60 229 66 88 142 117 74 301 411
2025/20262.573 346 565 922 740 0 0 0 0 0 0 0 0
Totale 9.440